In March last year, the Federal Trade Commission (FTC) joined with its EU, UK and Canadian counterparts to rethink their approach to M&A by “Big Pharma”. Arman Oruc, partner in the Antitrust and Competition practice at Goodwin, says the working group is still consulting. Read the Financial Times article here.